An analysis of the relationship between metastases and cachexia in lung cancer patients

Masatoshi Shiono, Kan Huang, Robert J. Downey, Nikita Consul, Nicolas Villanueva, Kristen Beck, Kathleen Fenn, Donald Dietz, Takuhiro Yamaguchi, Shunsuke Kato, Chaitanya Divgi, Kevin Kalinsky, Ying Wei, Yuan Zhang, Alain C. Borczuk, Akira Inoue, Balazs Halmos, Swarnali Acharyya

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

Weight loss and hematogenous metastases are poor prognosis factors in lung cancer patients that can but do not necessarily co-occur. We retrospectively investigated the clinical association between cachexia, tumor characteristics (such as metastatic burden and mutational status), and treatment in lung cancer patients. The medical records of 394 lung cancer patients from two institutions (Columbia University, USA and Tohoku University, Japan) were reviewed. Information collected included the presence of cachexia, histologic subtype, tumor stage, number of metastases, mutation status, treatment, and survival. Descriptive statistics were performed. Only stage IV patients exhibited >5% weight loss (0.8%, 2.2%, 3.6%, and 5.1%, for stages I to IV; P = 0.0001). Patients with metastases developed cachexia more often than patients without metastases independent of treatment (6.0% and 7.1% weight loss in patients with metastases vs. 2.5% and 2.0% in patients without metastases, before [P = 0.0001] and after [P < 0.0001] treatment, respectively). The change in number of metastatic sites over time correlated with increasing weight loss (5.2%, 10.6%, 13.4%, and 13.4%, for an increase of 0, 1, 2, and ≥3 metastatic sites, from initial diagnosis to the endpoint; P < 0.0001). Patients with cachexia had worse survival than patients without cachexia (hazard ratio, 2.94; 95% confidence interval, 2.08–4.16; P < 0.0001). Tumors with mutated KRAS were associated with an increased risk of weight loss (11.4% weight loss in patients with mutated KRAS vs. 6.0% in patients with wild-type KRAS; P = 0.0011). Our findings suggest that the capabilities of lung cancer to metastasize and cause cachexia might be linked intrinsically and are independent of treatments administered. KRAS-mutated tumors were more commonly associated with cachexia.

Original languageEnglish (US)
Pages (from-to)2641-2648
Number of pages8
JournalCancer Medicine
Volume5
Issue number9
DOIs
StatePublished - Sep 1 2016

    Fingerprint

Keywords

  • Cachexia
  • KRAS mutation
  • lung cancer
  • metastasis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Shiono, M., Huang, K., Downey, R. J., Consul, N., Villanueva, N., Beck, K., Fenn, K., Dietz, D., Yamaguchi, T., Kato, S., Divgi, C., Kalinsky, K., Wei, Y., Zhang, Y., Borczuk, A. C., Inoue, A., Halmos, B., & Acharyya, S. (2016). An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Medicine, 5(9), 2641-2648. https://doi.org/10.1002/cam4.841